Key result
Pyridostigmine reduced myocardial vulnerability to injury via the SIRT3/AMPK and IRS-1/Akt pathways in diabetic mice with isoproterenol-induced myocardial damage.
Why the study?
Whether pyridostigmine regulates glucose metabolism and mitochondrial homeostasis to reduce myocardial vulnerability to injury in diabetic mice was unknown.
Does pyridostigmine reduce myocardial vulnerability to injury in diabetic mice?
Does pyridostigmine reduce myocardial vulnerability to injury in diabetic mice?
Pyridostigmine protects against isoproterenol-induced myocardial damage in diabetic mice by regulating glucose metabolism and mitochondrial homeostasis via SIRT3/AMPK and IRS-1/Akt pathways.
May protect diabetic myocardium in mice; hypothesis-generating with no clinical translation yet.
Diabetic patients are more susceptible to myocardial ischemia damage than nondiabetic patients, with worse clinical outcomes and greater mortality. The mechanism may be related to glucose metabolism, mitochondrial homeostasis, and oxidative stress. Pyridostigmine may improve vagal activity to protect cardiac function in cardiovascular diseases. Researchers have not determined whether pyridostigmine regulates glucose metabolism and mitochondrial homeostasis to reduce myocardial vulnerability to injury in diabetic mice. In the present study, autonomic imbalance, myocardial damage, mitochondrial dysfunction, and oxidative stress were exacerbated in isoproterenol-stimulated diabetic mice, revealing the myocardial vulnerability of diabetic mice to injury compared with mice with diabetes or exposed to isoproterenol alone. Compared with normal mice, the expression of glucose transporters (GLUT)1/4 phosphofructokinase (PFK) FB3, and pyruvate kinase isoform (PKM) was decreased in diabetic mice, but increased in isoproterenol-stimulated normal mice. Following exposure to isoproterenol, the expression of (GLUT)1/4 phosphofructokinase (PFK) FB3, and PKM decreased in diabetic mice compared with normal mice. The downregulation of SIRT3/AMPK and IRS-1/Akt in isoproterenol-stimulated diabetic mice was exacerbated compared with that in diabetic mice or isoproterenol-stimulated normal mice. Pyridostigmine improved vagus activity, increased GLUT1/4, PFKFB3, and PKM expression, and ameliorated mitochondrial dysfunction and oxidative stress to reduce myocardial damage in isoproterenol-stimulated diabetic mice. Based on these results, it was found that pyridostigmine may reduce myocardial vulnerability to injury via the SIRT3/AMPK and IRS-1/Akt pathways in diabetic mice with isoproterenol-induced myocardial damage. This study may provide a potential therapeutic target for myocardial damage in diabetic patients.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2019) studied Diabetes with isoproterenol-induced myocardial damage. Pyridostigmine vs. Isoproterenol-stimulated diabetic mice without pyridostigmine was evaluated on Myocardial vulnerability to injury (myocardial damage, mitochondrial dysfunction, and oxidative stress). Pyridostigmine reduced myocardial vulnerability to injury via the SIRT3/AMPK and IRS-1/Akt pathways in diabetic mice with isoproterenol-induced myocardial damage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: